Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > REGULATORY
REGULATORY
- MHLW Selects Kitasato Univ. Hospital, FBRI as Base for Japan-Led Global Clinical Research
June 15, 2012
- Mr Umemura of DPJ Proposes Obligatory Use of Generics for Welfare Recipients
June 15, 2012
- MHLW Study Group Might Postpone Concrete Conclusion on Relief System for Victims of Health Damage Due to Anticancer Drugs
June 13, 2012
- Ryukaikon’s Working Team Prepares to Start Operations by End of June; Beginning with Exchange of Opinions between JPWA, NPhA
June 13, 2012
- With Consumption Tax Hike in 2015, “Focus on Whether to Conduct Market Price Survey”: EAD Director Kamata
June 12, 2012
- PAFSC Committee Gives Green Light to OTC Switching of Hyaluronate Sodium
June 11, 2012
- Committee on Non-Prescription Drugs Recommends Approval for Switch OTC Versions of Allegra
June 11, 2012
- Medical Community Expresses Caution on Deferment of Experimental Animal Regulations by DPJ
June 8, 2012
- Gov’t Council Finalizes 5-Year Medical Innovation Strategy Calling for Creation of Drug Discovery Support Network
June 8, 2012
- Expert Subcommittee Begins Discussions on Pricing of Long-Listed Drugs with Focus on Differences from Generic Prices
June 8, 2012
- Drug Cost Ratio in FY2009 was 22.3%, Up 1.1 Points from Previous Year: MHLW
June 8, 2012
- Local Governments Express Concern for IPV Price at 5,450 Yen
June 7, 2012
- Survey Highlights Successful Efforts of 5 Prefectures to Promote Generic Drug Use
June 6, 2012
- PAFSC 1st Committee on New Drugs Recommends Approval for Fibromyalgia Indication for Lyrica
June 5, 2012
- DPJ’s Proposal on 5-Year Innovation Strategy Calls for Subsidies to Reduce Consultation, Review Fees
June 4, 2012
- PAFSC’s 2nd Committee Recommends Approval for Pfizer Japan’s Axitinib
June 4, 2012
- MHLW Announces Addition of 5 APIs/8 Products to NHI Price List
June 1, 2012
- Cost-Effective Assessments “Not Appropriate” for Everything: MED Director Suzuki
May 31, 2012
- DPJ Proposal to Amend PAL Would Mandate Reporting of Package Inserts
May 31, 2012
- Specific Targets for New 5-Year Clinical Trial Activation Plan Expected by Late August
May 31, 2012
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…